Anticancer Activity of Brevinin-2R Peptide and its Two Analogues Against Myelogenous Leukemia Cell Line as Natural Treatments: An In Vitro Study

Human chronic myelogenous leukemia (CML) is a stem cell driven hematological malignancy which shows resistance to existing therapeutics. This property of CML accentuates the necessity to develop alternative anti-CML therapeutic agents. Herein, we have evaluated the anticancer activity of a novel anticancer peptide, Brevinin-2R and its two analogues, Brevinin-2R-C and Brevinin-2R-D regarding their inhibitory activity against K562 cells. Various cell-based analyses have been conducted to analyze the effects of these peptides and their mechanism of action. Hematotoxicity assay was performed to determine their hemolytic activities. MTT and neutral red uptake assays were conducted to examine anti-proliferative effects, propidium iodide (PI) staining to monitor the DNA content in different phases of cell cycle and Annexin V/PI staining to detect the apoptosis induction for the peptides. Our findings indicated that these peptides are capable of diminishing the cell growth and inducing apoptosis and cell cycle arrest. Brevinin-2R and its two analogues inhibited cell proliferation through strong cell cycle arrest in G2/M phase leading to apoptosis induction. The cytotoxicity of Brevinin-2R was higher than that of its two derivatives. These observations have provided new insights into the therapeutic activity of Brevinin-2R and its two analogues and suggest that these peptides have the potential to act as anticancer agents in treatment of K562. Further in vivo investigations on the therapeutic potential of Brevinin-2R and its two analogues are required to get a better grasp of their mechanism of action.